Study results released on Monday revealed that a personalized mRNA vaccine manufactured by Moderna and Merck has shown ...
Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration Targeting Inherited Kidney Diseases
Eli Lilly has expanded its genetic medicines pipeline and capabilities, agreeing to partner with Ascidian Therapeutics to develop RNA exon editors intended to treat inherited kidney diseases, through ...
A personalized mRNA vaccine may change melanoma treatment, with 70% of patients cancer-free after 5 years. Discover how this ...
Researchers delivered GM-CSF mRNA to the endometrium using targeted nanoparticles. Implantation was restored in injured mouse ...
Andrew L. Pecora, MD, discusses the significance of the long-term findings from the KEYNOTE-942 trial of intismeran autogene ...
A number of companies presented new data on their cancer vaccine candidates at ASCO 2026.
Advances in genomic testing are helping doctors identify which tumours truly need chemotherapy — and which patients may do ...
Bernstein 42nd Annual Strategic Decisions Conference May 28, 2026 10:00 AM EDTCompany ParticipantsStéphane Bancel - CEO ...
Morning Overview on MSN
A Boston-area trial just showed a single once-a-year shot of an mRNA vaccine pushed pancreatic-cancer patients into remission — built on each tumor’s own gen…
Eight people who had surgery for pancreatic cancer and then received a vaccine built from their own tumor DNA have now gone ...
For patients with high-risk resected melanoma, adding the mRNA vaccine intismeran to pembrolizumab continued to stave off recurrence and distant metastases at 5 years.
James F. Howard, MD, discusses what he believes will be the next steps in treating myasthenia gravis. CAR-T therapies could ...
Biotech is starting to sound less like medicine and more like software, and SpaceX and Tesla CEO Elon Musk thinks that shift ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results